

Research article

Open Access

Two previously proposed P₁/P₂-differentiating and nine novel polymorphisms at the A4GALT (P^k) locus do not correlate with the presence of the PI blood group antigen

Åsa Hellberg, M Alan Chester and Martin L Olsson*

Address: Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University and the Blood Centre, Lund University Hospital, Lund, Sweden

Email: Åsa Hellberg - asa.hellberg@med.lu.se; M Alan Chester - Alan.Chester@med.lu.se; Martin L Olsson* - Martin_L.Olsson@med.lu.se

* Corresponding author

Published: 07 October 2005

Received: 28 March 2005

BMC Genetics 2005, 6:49 doi:10.1186/1471-2156-6-49

Accepted: 07 October 2005

This article is available from: <http://www.biomedcentral.com/1471-2156/6/49>

© 2005 Hellberg et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The molecular genetics of the P blood group system and the absence of PI antigen in the p phenotype are still enigmatic. One theory proposes that the same gene encodes for both the PI and P^k glycosyltransferases, but no polymorphisms in the coding region of the P^k gene explain the P₁/P₂ phenotypes. We investigated the potential regulatory regions up- and downstream of the A4GALT (P^k) gene exons.

Results: P₁ (n = 18) and P₂ (n = 9) samples from donors of mainly Swedish descent were analysed by direct sequencing of PCR-amplified 5'- and 3'-fragments surrounding the P^k coding region. Seventy-eight P₁ and P₂ samples were investigated with PCR using allele-specific primers (ASP) for two polymorphisms previously proposed as P₂-related genetic markers (-551₋550insC, -160A>G). Haplotype analysis of single nucleotide polymorphisms was also performed with PCR-ASP. In ~1.5 kbp of the 3'-untranslated region one new insertion and four new substitutions compared to a GenBank sequence (AL049757) were found. In addition to the polymorphisms at positions -550 and -160, one insertion, two deletions and one substitution were found in ~1.0 kbp of the 5'-upstream region. All 20 P₂ samples investigated with PCR-ASP were homozygous for -550insC. However, so were 18 of the 58 P₁ samples investigated. Both the 20 P₂ and the 18 P₁ samples were also homozygous for -160G.

Conclusion: The proposed P₂-specific polymorphisms, -551₋550insC and -160G, found in P₂ samples in a Japanese study were found here in homozygous form in both P₁ and P₂ donors. Since P² is the null allele in the P blood group system it is difficult to envision how these mutations would cause the P₂ phenotype. None of the novel polymorphisms reported in this study correlated with P₁/P₂ status and the PI/p mystery remains unsolved.

Background

The P-related blood groups include four antigens that are predominantly of glycolipid nature and occur in related biosynthetic pathways [1].

The GLOB blood group system [International Society of Blood Transfusion (ISBT) number 028] comprises the P antigen and the GLOB collection (ISBT number 209) includes the P^k antigen and also LKE that is not discussed

Table 1: The P/GLOB blood groups.

Phenotype	Frequency	Antigen present on RBC	Antibodies in serum
P ₁	20–90% ^a	PI, P ^k , P	none
P ₂	10–80% ^a	P ^k , P	Anti-PI
p	rare ^b	none	Anti-PP P ^k
P ₁ ^k	rare	PI, P ^k	Anti-P
P ₂ ^k	rare	P ^k	Anti-PP

^a These frequencies differ significantly between different populations. E.g. the frequency of P₁ vs. P₂ are virtually the opposite when Caucasians (80 vs. 20%) and Japanese (20 vs 80%) are compared.

^b While the frequency of this phenotype has been estimated at 1 per million, two population groups, Swedes and Amish people, have significantly higher numbers (e.g. 141 per million in Västerbotten county in Northern Sweden [21]).




Figure 1
Biosynthetic pathways relating the P₁, P and P^k glycolipids.

further here [2]. The P₁ antigen is assigned to ISBT system number 003. Five phenotypes depending on the presence or absence of the three antigens, P₁, P and P^k, are known (Table 1). The presence of all three antigens results in the P₁ phenotype but absence of the P₁ antigen causes the P₂ phenotype. If both P₁ and P are absent the phenotype P₂^k arises. Absence of P but presence of P₁ and P^k results in the P₁^k phenotype. Absence of all three antigens results in the p phenotype. In each of the phenotypes naturally occurring-antibodies can arise against the missing antigen,

invariably so in the case of P and P^k but less frequently for P₁. These phenotypes can be explained biochemically by the presence or absence of some of the enzymes shown to catalyse the pathways shown in Figure 1.

The P₁ antigen is present on hematopoietic cells [3,4] and other cells [5]. The strength of the antigen expression can differ from one person to another and it seems to be dependent on gene dosage [1]. Frequencies of the P₁ phenotype vary in different ethnic groups, for example, ~80%




Figure 2
Schematic picture of the exon/intron structure of the A4GALT (*P^k*) gene and the positions of the 19 polymorphisms investigated. The numbering systems used are as follows: The 5'-region and exon 1 are described using the same numbering as Iwamura *et al.* [15] for easy comparison. Intron 1 and exon 2 are numbered from the first nucleotide of each element, with the number being preceded by int1- or ex2-, respectively. The adenosine of the translation start codon ATG in exon 3 is defined as nt. 1. Nucleotides upstream from this (untranslated exon 3 and the 3'-region of intron 2) are given as negative numbers. The exons are represented by rectangles and the intervening introns by triangles. Exons 1–3 are 21, 145 and 1059 bp long, respectively and introns 1 and 2 are approximately 25 and 1.5 kbp long, respectively.

of Caucasians are P_1 , compared to only ~20% of Asians [1]. This may be due to selective pressure since P1 and related antigens can act as cellular receptors for microorganisms and biotoxins [5].

Two genes that code for the P^k - and P-synthesizing enzymes, 4- α -galactosyltransferase ($\alpha 4$ GalT, Gb3 synthase) [6] and 3- β -N-acetylgalactosaminyltransferase ($\beta 3$ GalNAcT, globoside/Gb4 synthase) [7], respectively, have been cloned. Subsequently, numerous mutations have been found to explain the rare P_1^k , P_2^k [8,9] and p [6,9-12] phenotypes.

The molecular genetic background of the P1 antigen remains unknown. Several theories exist, including one model suggesting that the same $\alpha 4$ GalT is able to transfer galactosyl residues to both lactosylceramide and paragloboside but in order to use the latter as the acceptor, a regulatory protein is required [13]. Another model postulates the existence of two different enzymes, and thus two genes, requiring both of them to be inactivated to cause the p phenotype [13]. A third model proposes a single gene with three alleles, one allele coding for an $\alpha 4$ GalT that can utilise lactosylceramide and paragloboside as acceptors, one allele using lactosylceramide only and the

third allele coding for an inactive form of the transferase [14]. However, none of the known polymorphisms (109A>G, 903G>C, 987G>A) in the coding region of the P^k gene explains the P_1/P_2 phenotypes [6].

Recently, Iwamura *et al.* [15] suggested that transcriptional regulation caused by two polymorphisms (-551_-550insC, -160A>G) in the 5'-upstream region of the P^k gene might be the reason for the P_1/P_2 phenotypes.

The P^k gene was originally thought to comprise two exons, but recent GenBank depositions indicate the presence of three exons with the whole coding region in exon 3, as shown in Figure 2. Various publications have considered different transcription starting points resulting in different numbering of the same nucleotide positions. The numbers used here are described in the legend to Figure 2.

In this study we have investigated an extended sequence surrounding the coding region of the P^k gene including untranslated exons and intronic portions as well as potentially regulatory regions 5' or 3' of the transcribed region. Contrary to a previous report [15], we found no clear-cut correlation with the P_1/P_2 phenotype, neither between previously described polymorphisms in the 5'-regulatory

Table 2: The occurrence of the -550T;-160A and -551_-550insC;-160G haplotypes in individuals with various P phenotypes.

Phenotype	No.	Combination of polymorphisms		
		-550T;-160A (homozygous)	-550T;-160A - 551_-550insC;-160G (heterozygous)	-551_-550insC;-160G (homozygous)
P ₁	58	8	32	18
P ₂	20	0	0	20
P ₁ ^k	3	0	2	1
P ₂ ^k	3	0	1	2
p	20	3	1	16

region, nor any of the novel polymorphisms reported in this study.

Results

Screening for the -551_-550insC and -160A>G polymorphisms by PCR-ASP

Seventy-eight samples were screened for the two genetic markers previously [15] suggested to cause the P₂ phenotype. The results are summarized in Table 2. Two haplotypes, -550T;-160A and -551_-550insC;-160G, were found whilst the other theoretically possible haplotypes, 550T;-160G and -551_-550insC;-160A, were not detected in this study. Each of the 20 samples, that were phenotyped as P₂ were homozygous for both -551_-550insC and -160A>G, which could indicate that these polymorphic positions were indeed P₂-specific as proposed. However, 18 of the 58 P₁ samples investigated were also homozygous for the same polymorphic markers. Of the remaining P₁ samples, 32 were heterozygous at both nucleotide positions and only eight samples were homozygous for the proposed P₁-specific combination, -550T;-160A. Twenty-nine of the 32 heterozygous samples were available for analysis by two haplotype-specific PCR reactions (-550T;-160A and -551_-550insC;-160G). All samples were positive in both PCR reactions, indicating that the samples were heterozygous for the combinations -550T;-160A and -551_-550insC;-160G and not for -550T;-160G and -551_-550insC;-160A. Additionally, 26 samples with the rare phenotypes P₁^k (n = 3), P₂^k (n = 3) and p (n = 20) were screened. One of the P₁^k samples was homozygous for the genetic markers reported to be associated with the P₂ phenotype, and the other two were heterozygous. Of the P₂^k samples two had the expected polymorphisms (-551_-550insC;-160G), but the third P₂^k was heterozygous and thus the first reported sample that lacks the P1 antigen in spite of a genotype not homozygous for the -551_-550insC and -160G markers. Sixteen of the 20 p samples were homozygous for -551_-550insC;-160G, thus consistent with their lack of P1, but one was heterozygous and three were homozygous for -

550T;-160A. Due to lack of available DNA from these rare individuals the haplotype-specific PCR was only run on one of the four heterozygous samples. As above, this sample was also positive in both PCR reactions.

Amplification of the 5'-, 3'- and coding regions of the P^k gene for DNA sequencing

Ten of the 18 P₁ samples with P₂-associated polymorphisms (-551_-550insC;-160G) were chosen for further investigation by sequencing the 5'-region and the 3'-region, as were all eight P₁(-550T;-160A) and nine of the 20 P₂ samples. In three samples from each category the whole P^k gene reading frame, located in exon 3, was also sequenced.

In the 5'-region upstream of exon 1, four novel polymorphisms were detected compared to a sequence deposited in GenBank (accession number AL049757). These findings comprised a substitution (-770C>T), an insertion (-107_-106insG) and two deletions (-907_-903del and -17_8del). Interestingly, the latter deletion is located across the border of the 5'-region and exon 1.

In the 3'-UTR, five new polymorphisms were found, four of which were substitutions (1409G>A, 1495C>A, 1523G>A, 1697G>A) and one was an insertion (1592dupG). Figure 2 shows the relative positions of the polymorphisms investigated.

The distribution of the polymorphisms in the three different categories, P1(-550T;-160A), P1(-551_-550insC;-160G) and P2 are shown in Figure 3. As can be seen, none of the polymorphisms is a genetic marker specific for the P₂ phenotype. On the other hand, individuals from the P1(-550T;-160A) category are homozygous for 12 of the 16 investigated polymorphisms. However, when individuals from the P1(-551_-550insC;-160G) samples are included such pattern is no longer evident. It can also be noted that the frequency of some of the variants appears




Figure 3
The distribution of the polymorphic variants in the three different sample categories: P1(-550T;-160A), P1(-551_-550insC;-160G) and P2. The diagram shows data of 16 polymorphisms investigated. The data for the 5'- and the 3'-regions were obtained by sequencing while most of the data for exon 3 originated from PCR-ASP analysis. Eight, P1(-550T;-160A), ten P1(-551_-550insC;-160G) and nine P2 samples were investigated. However, for the 903C>G polymorphism the corresponding numbers were five, five and seven samples. In position -107_-106 all investigated samples had three guanines instead of two as reported in the reference sequence (AL049757). We therefore do not consider this position as polymorphic in our analysis and it is consequently not included in this figure. cons. = consensus.

Table 3: Correlation of phenotype and haplotype

Phenotype	No. of samples	Polymorphism					Haplotype	No. of haplotypes
		-550	-160	109	987	1697		
P ₁	10	insC	G	A	G	G	A-1	15
		insC	G	G	A	A	A-2	5
P ₁	8	T	A	A	G	G	B-1	2
		T	A	G	A	A	B-2	12
		T	A	G	A	G	B-3	2
P ₂	9	insC	G	A	G	G	A-1	15
		insC	G	G	A	A	A-2	3

to be relatively low, less than ~10 %, for six of the polymorphic sites analyzed.

While sequencing exon 3, an unexpected mutation, 441G>A, was encountered in a P₁ sample of African origin. No other samples, including two of African descent, examined in this study had this particular mutation, which would not alter the amino acid sequence, or any other new polymorphisms.

Haplotype analysis of SNPs in the reading frame and a polymorphism in the 3'-UTR using PCR-ASP

We also performed PCR-ASP utilising polymorphisms in exon 3 and in the 3'-UTR of the *P^k* gene to determine the *cis/trans* linkage of SNPs and to establish if combinations of polymorphisms correlated with specific alleles. The SNPs chosen were two of those previously described, i.e. 109A>G and 987G>A. Analysis of the polymorphism 903C>G was considered unnecessary due to its proximity to nt. 987. In addition, of the new polymorphisms the one furthest downstream (1697G>A) was analyzed. The results are summarized in Table 3. None of the haplotypes correlated well with the P₁/P₂ phenotypes although 83% of the alleles among the P₂ samples and 75% of the P₁(-551_-550insC;-160G) category samples had the A-1 haplotype, whilst in the P₁(-550T;-160A) category samples only 12.5% had this partial haplotype (B-1). The remaining alleles in this latter category consisted of 12.5% of the rare B-3 and 75% of the B-2 haplotype.

Discussion

The molecular background of the P blood group system has been a subject of speculation since its discovery. Antigens formed as a result of closely related biosynthetic pathways are now known to arise from independent genetic loci. However, the current paradox revolves around the 4- α -galactosyltransferase (α 4GalT) that syn-

thesises the P^k antigen and possibly also the P₁ antigen. If it is indeed exactly the same enzyme synthesizing both, then the P₂ and P₂^k phenotypes should not exist, as the P₁-synthesizing α 4GalT that is lacking in these individuals should also result in the loss of the P^k and, subsequently, P antigens. The absence of the P₁ antigen is not due to a defect in the biosynthesis of paragloboside since this glycolipid is a major precursor of the erythrocyte ABH antigens that are unaffected by the P₁/P₂ status. The absence of P₁ antigen in the P₂ phenotype is likely to be caused by inefficient or absent glycosyltransferase activity that can be due to a structural defect in the enzyme itself or more indirectly due to various other factors necessary to ensure the enzyme's optimal expression, localisation and efficiency[1]. Studies are currently in progress to analyse A4GALT mRNA by real-time PCR and other methods.

The P₁ and P^k antigens both share the same terminal carbohydrate structure and therefore the question arises whether the same enzyme is, or is not, synthesizing both antigens. Various theories exist but so far none has been proven correct. Recently Iwamura *et al* [15] proposed that the P₁ synthase is identical to the P^k synthase and that the phenotypic difference may be caused by two polymorphisms, -160A>G and -551_-550insC, found in the 5'-upstream regulatory region. Unfortunately, these authors were not able to show any functional effects of these two polymorphisms, at least not when tested in a fibroblast cell line. As they commented themselves, a haematopoietic cell line, preferentially even an erythropoietic one, would have been the optimal choice for the challenge but was technically difficult. Iwamura *et al.* also demonstrated the presence of cryptic and intracellular P₁ antigen in cells from individuals known to have the P₂ red blood cell phenotype. Whether this surprising finding is method-dependent or may differ between populations is currently unclear.

Our data indicate that an individual's P₁/P₂ status is not due to the -551_-550insC;-160G haplotype, contrary to the previously published indication [15]. However, it is striking that all (except one P₂^k) samples with the P₂ phenotype tested here have the same -551_-550insC;-160G haplotype as all ten P₂ samples tested by Iwamura *et al.* This clearly argues that the genetic linkage between the A4GALT locus and P₂ status must be relatively strong. The results shown in Figure 3 indicate that none of the 16 polymorphic markers investigated can predict the serologically determined P₁/P₂ status. It is also interesting to note the high frequency with which SNPs occur in the A4GALT gene, as opposed to the gene coding for the next glycosyltransferase in this biosynthetic pathway, the P synthase, in which we have found no variations at all. The only exceptions are rare mutations causing the P₁^k and P₂^k phenotypes [8,9]. Despite the apparent variability in the A4GALT gene, the current study suggests that a limited number of haplotypes, with the A-1 and B-2 haplotypes being the predominant ones in the Swedish population, may constitute genetic clusters within which further variation has arisen (as judged by the lack of homogeneity within each group, see Table 3), still without obvious correlation to the blood group phenotype.

However, all this does not differentiate between the one-gene theory and the possibility of a tightly coupled independent locus responsible for P₁ antigen expression. Since there are no apparent α4GalT homologues in this genetic region this may imply that a hypothetical second closely linked gene would give rise to *either* a regulatory molecule modifying the acceptor specificity of the P^k-synthesizing α4GalT (analogous to lactose synthetase [16]) *or* a chaperone type of molecule to make a fraction of the α4GalT molecules more suitably located/positioned for P₁ synthesis. The finding of intracellular P₁ antigen in P₂ individuals [15], would tend to support the latter possibility. Chaperones have been shown to be involved in processes related to glycosyltransferase action [17] but it is somewhat difficult (although not impossible) to imagine an α4GalT-specific chaperone to be the solution for this long-standing enigma.

Conclusion

The study of potential regulatory regions surrounding the P^k coding sequence revealed nine previously unreported polymorphisms but none of them correlated with the P₁/P₂ red blood cell phenotypes. Two polymorphisms, -551_-550insC and -160A>G, suggested to cause the P₂ phenotype in Japanese individuals [15] were found in homozygous form also in P₁ samples in this study and since the P₂ is the null phenotype of this blood group system, it is therefore very unlikely that these mutations cause the P₂ phenotype.

Methods

Blood samples and DNA preparation

Samples with the P₁ (n = 58) and P₂ (n = 20) phenotypes were chosen from our in-house panel of test erythrocytes. The majority of the donors are of Swedish origin but a few are of Asian or African descent. Three P₁^k, three P₂^k and 20 p samples, genetically characterized in our laboratory, were also included for screening purposes [8,9,12,18]. The erythrocyte phenotype was determined by standard serological techniques.

DNA was prepared from EDTA blood using a simple salt-ing-out method for small volumes modified from Miller *et al.* [19], or Qiagen QIAmp Blood Extraction kit (Qiagen GmbH, Hilden, Germany). The DNA was dissolved in H₂O at a concentration of 100 ng/μl.

Screening for the -551_-550insC and -160A>G polymorphisms by PCR-ASP

All oligonucleotide primers used in the study were synthesized by DNA Technology ApS (Aarhus, Denmark) and the sequences are shown in Table 4. PCR with allele-specific primers designed to detect the polymorphisms at -551_-550insC and -160A>T, described to cause the P₂ phenotype [15] was performed. For all heterozygous samples double allele-specific amplification, -551_-550insC;-160G and -550T;160A, were performed. The primer combinations used are listed in Table 5 and the locations in Figure 4. Primers were mixed with 100 ng of genomic DNA, 2 nmol of each dNTP, 2% glycerol, 1% cresol red and 0.5 U of AmpliTaq Gold (Perkin Elmer/Roche Molecular Systems, Branchburg, NJ, USA) in 10 × PCR buffer with 15 mM MgCl₂. The final reaction volume was 11 μl. Thermocycling was undertaken in GeneAmp PCR system 2400/2700 (Perkin-Elmer/Cetus, Norwalk, CT, USA) under PCR conditions described in Table 5.

Amplification of the 5'-, 3'- and coding regions of the P^k gene for DNA sequencing

The coding region, exon 3, in the P^k gene was amplified with the primer pair Pk-(-140)-F and Pk-1120-R in the Expand High Fidelity PCR System (Roche Molecular Systems, Pleasanton, CA, USA) and sequenced as previously described [12].

The 5'-regulatory region of the P^k gene was amplified with primers Pk-5'-(-1056)-F and Pk-int1-160-R and Pk-5'-(-131)-F and Pk-int1-160-R. Amplification was performed in a reaction volume of 22 μL with four pmol of each primer, 2 nmol of each dNTP, 100 ng of genomic DNA, GC-rich enzyme mix (0.5 U per reaction), GC-rich resolution solution and buffer with a final MgCl₂ concentration of 1.5 mM (GC-rich PCR System, Roche Diagnostics GmbH, Mannheim, Germany). Thermocycling was undertaken in GeneAmp PCR system 2400/2700 (Perkin-

Table 4: Oligonucleotide primers used in this study.

Primer name	Nucleotide sequence (5'→3')	Function
Pk-5'-(-1056)-F†	ACAGCCTGTGATGGGAATGAC	a, b, e
Pk-5'-(-740)-R†	TTGAGTGCTGACGCCCATCC	b
Pk-5'-(-834)-F	TGGGCACCCATTGAGTGCCA	b, e
Pk-5'-(-550)-R	ACCTCGCCCCATCTTCACAC	e
Pk-5'-(-550T)-F	GAACAAATTACCAATAGCAATATGT	e
Pk-5'-(-550insC)-R	CCTCGCCCCATCTTCACAGC	e
Pk-5'-(-550insC)-F	AACAAATTACCAATAGCAATATGCT	e
Pk-5'-(-477)-F	GCGGCTTAAGGATACAGCAA	b
Pk-5'-(-418)-R	CTGATCCCACCGCCTCCTG	b
Pk-5'-(-235)-F	GCGCTCCCTACCTGTTGGC	b
Pk-5'-(-131)-F	GGACCGGGACCCGCAGGG	a, b
Pk-5'-(-160Gmis)-R	CCCGGTCCCCAGAGC <u>ACC</u>	e
Pk-5'-(-160Amis)-R	CCCGGTCCCCAGAGC <u>ACT</u>	e
Pk-5'-(-160G)-R	CCCGTCCCCAGAGCCCTC	e
Pk-5'-(-160A)-R	CCCGGTCCCCAGAGCCCTT	e
Pk-int1-35-R	CGTCCCCCGCAACATCGGC	b
Pk-int1-160-R	GCACAAATGTCGCCTCCAGAA	a, b
Pk-ex2-74_75insC-F	AGGTTCGGCTGCTGAGCCCA	e
Pk-int2-R	GGGTGCAACCTGATTGCTAAG	e
Pk-109G-F	TTCACGTTTTTCGTCTCCATCG	e
Pk-109A-F	TTCACGTTTTTCGTCTCCATCA	e
Pk-987G-F	CACGCGGTTTCGAGGCCACG	e
Pk-987A-F	CACGCGGTTTCGAGGCCACA	e
Pk-1120-R	GGAAGGGCGGCCAGTGC	e
Pk-1006-F	CCAGGGCACTGCTGGCCC	c, d
Pk-1253-F	GGACAGTGTCTGTCTCGAG	d
Pk-1697G-R	CCTGTCTGAGGGAAGGGGC	e
Pk-1697A-R	CCCTGTCTGAGGGAAGGGGT	e
Pk-1791-R	TTATTCTATTGATTATTCTCCTGTG	d
Pk-1881-R	CCCCGTCAGAAGAATGGAGC	c, d
HGH-F	TGCCTTCCCAACCATTCCCTTA	f
HGH-R	CCACTCACGGATTTCTGTTGTGTTTC	f
JK-781-L-F	GCATGCTGCCATAGGATCATTGC	f
JK-943-L-R	GAGCCAGGAGGTGGGTTTGCC	f
MO-21	GGTGAGAGAAGGAGGGTGAG	f
MO-31	CCAGCACCCCGGCCAGCA	f

† F = Forward. R = Reverse. The underlined nucleotide is mismatched for better specificity.

a. used for amplification of the 5' regulatory region.

b. used for sequencing of the 5' regulatory region.

c. used for amplification of the 3'-UTR.

d. used for sequencing the 3'-UTR.

e. used for PCR-ASP.

f. used as internal control.

Elmer/Cetus): Initial denaturation at 96°C for 7 min followed by 10 cycles at 94°C for 30 s, 62°C for 30 s and 72°C for 1 min and then 25 cycles at 94°C for 30 s, 60°C for 30 s and 72°C for 1 min.

For the 3'-region of the *Pk* gene 5 pmol of primers Pk-(1006)-F and Pk-(1881)-R were mixed with 100 ng of genomic DNA, 2 nmol of each dNTP, 2% glycerol, 1% cresol red and 0.5 U of AmpliTaq Gold (Perkin Elmer/Roche Molecular Systems) in 10 × PCR buffer with 15 mM MgCl₂. The final reaction volume was 11 µl. PCR was run

at 96°C for 7 min followed by 35 cycles at 94°C for 30 s, 64°C for 30 s and 72°C for 1 min.

PCR products were excised from 3% agarose gels (Seakem, FMC Bioproducts, Rockland, ME, USA) stained with ethidium bromide (0.56 mg/l gel, Sigma Chemicals, St. Louis, MO, USA) following high-voltage electrophoresis and purified using Qiaquick gel extraction kit (Qiagen). The Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 310 Genetic Analyser (Applied Biosystems) were used for

Table 5: Oligonucleotide primer combinations and PCR conditions (previously not described) used for PCR-ASP in this study.

Primer combination	Specific primer (pmol)	Control primer			DMSO (%)	Annealing temperature (°C)	Extension time (sec)
		HGH-F/R (pmol)	JK-L-F/R (pmol)	MO-21/31 (pmol)			
Pk-5'(-1056)-F Pk-5'(-550)-R	5 5	1				64	40
Pk-5'(-1056)F Pk-5'(-550insC)-R	5 5	1				64	40
Pk-5'(-834)-F Pk-5'(-160A-mis)-R	7.5 7.5		0.5		4	62	60
Pk-5'(-834)-F Pk-5'(-160G-mis)-R	5 5		0.5		3	62	60
Pk-5'(-550insC)-F Pk-5'(-160G)-R	10 10			0.75 0.75		64	40
Pk-5'(-550T)-F Pk-5'(-160A)-R	7.5 7.5			0.5 0.5		63	40
Pk-109A-F or Pk-109G-F Pk-1697A-R or Pk-1697G-R*	6 6	0.4			2	65	90
Pk-987A-F Pk-1697A-R	5 5	0.4				66	60
Pk-987G-F Pk-1697G-R	5 5	0.4				66	60
Pk-109A-F or Pk-109G-F Pk-1120-R**	7.5		0.5			64	60

Denaturation was carried out at 96°C for 7 min followed by 35 cycles at 94°C for 30 s. The annealing time was 30 s.

* Four double allele-specific amplifications were performed.

** These combinations were used for allele-specific amplifications for sequencing purposes.

direct DNA sequencing with capillary electrophoresis and automated fluorescence-based detection according to the manufacturer's instructions. Besides the PCR primers, internal primers were used as sequencing primers, see Table 4. To avoid detection of artefacts, sequencing was performed on both strands and using independently obtained fragments.

Detection of an insertion in exon 2 and linkage of SNPs in the reading frame with a polymorphism in the 3'-UTR using PCR-ASP

PCR-ASP for a previously found insertion, 75dupC in exon 2 (then believed to be exon 1), was also performed as described [12]. PCR-ASP was performed to investigate if the polymorphisms at nt. 109, 987 and 1697 were present in an allele-specific pattern. The reaction mixtures comprised 100 ng of genomic DNA, 2 nmol of each dNTP, 2% glycerol, 1% cresol red and 0.5 U of AmpliTaq




Figure 4
Schematic representation of the primers used to identify the polymorphisms at -551_-550insC and -160A>T, described to cause the P₂ phenotype. The figure also shows combinations and positions for the primers used to detect a linkage phase of SNPs in the reading frame with a polymorphism in the 3'-UTR. For size reference, see Figure 2.

Gold (Perkin Elmer/Roche Molecular Systems) in 10 × PCR buffer with 15 mM MgCl₂. The final reaction volume was 11 μl. Primer combinations and PCR conditions are described in Figure 4 and Table 5.

List of abbreviations

ASP, allele specific primer

bp, base pairs

ins, insertion

del, deletion

kb, kilo bases

PCR, polymerase chain reaction

SNP, single nucleotide polymorphism

UTR, untranslated region

ISBT, International Society of Blood Transfusion.

Authors' contributions

ÅH carried out the experimental studies and participated in the discussion and preparation of the manuscript. AC participated in the discussion and preparation of the manuscript. MLO contributed to the design and coordination of the study and participated in preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Sources of support: This work was supported in part by the Swedish Research Council (project no. K2005-71X-14251), the Medical Faculty at Lund University, governmental ALF research grants to Lund University

Hospital, the Inga & John Main Foundation for Medical Research and the Lund University Hospital Donation Funds.

Part of this study has previously been reported in abstract form at the 28th Congress of the International Society of Blood Transfusion held in Edinburgh, UK, on 11–15 July 2004 [20].

References

- Daniels G: *Human Blood Groups* 2nd edition. Oxford, UK, Blackwell Scientific; 2002.
- Daniels GL, Fletcher A, Garratty G, Henry S, Jorgensen J, Judd WJ, Levene C, Lomas-Francis C, Moulds JJ, Moulds JM, Moulds M, Overbeeke M, Reid ME, Rouger P, Scott M, Sistonon P, Smart E, Tani Y, Wendel S, Zelinski T: **Blood group terminology 2004: from the International Society of Blood Transfusion committee on terminology for red cell surface antigens.** *Vox Sang* 2004, **87**:304-316.
- Dunstan RA: **Status of major red cell blood group antigens on neutrophils, lymphocytes and monocytes.** *Br J Haematol* 1986, **62**:301-309.
- Dunstan RA, Simpson MB, Rosse WF: **Presence of P blood group antigens on human platelets.** *Am J Clin Pathol* 1985, **83**:731-735.
- Spitalnik PF, Spitalnik SL: **The P blood group system: biochemical, serological, and clinical aspects.** *Transfus Med Rev* 1995, **9**:110-122.
- Steffensen R, Carlier K, Wiels J, Lavery SB, Stroud M, Cedergren B, Nilsson SB, Bennett EP, Jersild C, Clausen H: **Cloning and expression of the histo-blood group P_k UDP-galactose: Gal-beta1-4Glc-beta1-Cer alpha1,4-galactosyltransferase. Molecular genetic basis of the p phenotype.** *J Biol Chem* 2000, **275**:16723-16729.
- Okajima T, Nakamura Y, Uchikawa M, Haslam DB, Numata SI, Furukawa K, Urano T, Furukawa K: **Expression cloning of human globoside synthase cDNAs. Identification of beta3Gal-T3 as UDP-N-acetylgalactosamine:globotriaosylceramide beta1,3-N-acetylgalactosaminyltransferase.** *J Biol Chem* 2000, **275**:40498-40503.
- Hellberg Å, Poole J, Olsson ML: **Molecular basis of the globoside-deficient P_k blood group phenotype. Identification of four inactivating mutations in the UDP-N-acetylgalactosamine:globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase gene.** *J Biol Chem* 2002, **277**:29455-29459.
- Hellberg Å, Ringressi A, Yahalom V, Safwenberg J, Reid ME, Olsson ML: **Genetic heterogeneity at the glycosyltransferase loci underlying the GLOB blood group system and collection.** *Br J Haematol* 2004, **125**:528-536.
- Furukawa K, Iwamura K, Uchikawa M, Sojka BN, Wiels J, Okajima T, Urano T, Furukawa K: **Molecular basis for the p phenotype.**

Identification of distinct and multiple mutations in the alpha1,4-galactosyltransferase gene in Swedish and Japanese individuals. *J Biol Chem* 2000, **275**:37752-37756.

11. Koda Y, Soejima M, Sato H, Maeda Y, Kimura H: **Three-base deletion and one-base insertion of the alpha(1,4)galactosyltransferase gene responsible for the p phenotype.** *Transfusion* 2002, **42**:48-51.
12. Hellberg Å, Steffensen R, Yahalom V, Sojka BN, Heier HE, Levene C, Poole J, Olsson ML: **Additional molecular bases of the clinically important p blood group phenotype.** *Transfusion* 2003, **43**:899-907.
13. Naiki M, Marcus DM: **An immunochemical study of the human blood group PI, P, and PK glycosphingolipid antigens.** *Biochemistry* 1975, **14**:4837-4841.
14. Graham HA, Williams AN: **A genetic model for the inheritance of the P, PI and Pk antigens.** *Immunol Commun* 1980, **9**:191-201.
15. Iwamura K, Furukawa K, Uchikawa M, Sojka BN, Kojima Y, Wiels J, Shiku H, Urano T, Furukawa K: **The blood group PI synthase gene is identical to the Gb3/CD77 synthase gene. A clue to the solution of the PI/P2/p puzzle.** *J Biol Chem* 2003, **278**:44429-44438.
16. Hill RL, Brew K: **Lactose synthetase.** *Adv Enzymol Relat Areas Mol Biol* 1975, **43**:411-490.
17. Ju T, Cummings RD: **A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase.** *Proc Natl Acad Sci U S A* 2002, **99**:16613-16618.
18. Hellberg Å, McGrath C, Reid ME, Olsson ML: **A novel missense mutation in the A4GALT gene of Amish individuals with the p phenotype.** *Transfusion* 2003, **43**:99A.
19. Miller SA, Dykes DD, Polesky HF: **A simple salting out procedure for extracting DNA from human nucleated cells.** *Nucleic Acids Res* 1988, **16**:1215.
20. Hellberg Å, Chester MA, Olsson ML: **Sixteen polymorphic sites in the 5'/3'-UTR of the Pk gene do not correlate with PI/P2 phenotypes.** *Vox Sanguinis* 2004, **87**:P18.11.
21. Cedergren B: **Population studies in northern Sweden. IV. Frequency of the blood type p.** *Hereditas* 1973, **73**:27-30.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

